Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.91 USD | -7.50% | -6.87% | -21.03% |
Jun. 05 | Morgan Stanley Adjusts COMPASS Pathways Price Target to $23 From $30, Maintains Overweight Rating | MT |
Jun. 04 | FDA panel to review psychedelic drug MDMA for first time | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.03% | 473M | |
+55.55% | 59.28B | |
+43.17% | 40.94B | |
-4.71% | 40.17B | |
-5.56% | 28.69B | |
+13.76% | 26.63B | |
-22.00% | 18.89B | |
+31.50% | 12.46B | |
+2.16% | 12.42B | |
+25.70% | 12.26B |
- Stock Market
- Equities
- CMPS Stock
- News COMPASS Pathways plc
- Morgan Stanley Initiates COMPASS Pathways at Overweight With $30 Price Target